Skip to main content

Advertisement

SpringerLink
Log in

Breast Cancer Diagnosis and Treatment in Low- and Mid-Resource Settings: the Role of Resource-Stratified Clinical Practice Guidelines

  • Global Breast Cancer (BO Anderson and C Duggan, Section Editors)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

One of the most important recent advances in the management of cancer patients have become the development of guidelines. Guidelines are usually evidence-based or international consensus guidelines. Those guidelines may not be applicable worldwide, especially where resources are limited. This prompted initiatives for the development of resource-stratified guidelines so that health care providers and authorities can do the best they can with the resources they have, while working on improving their resources. We will describe the process of development of those guidelines and briefly review recommendations for awareness, screening, diagnosis, and treatment of breast cancer, focusing on countries and special populations with limited resources.

Recent Findings

The World Health Organization (WHO) described three resource scenarios (low-resource, middle-resource, and high-resource scenarios) in order to facilitate the establishment of national cancer control plans. The Breast Health Global Initiative (BHGI), as an initiative group with goals to improve the care of patients with breast cancer in low- and mid-resource settings, identified four levels of resource availability (basic, limited, enhanced, and maximal) with comprehensive sets of recommendations for each. BHGI published resource-stratified breast cancer guidelines starting in 2006, and later on updated them and focused on implementation and health systems. The National Comprehensive Cancer Network (NCCN) initiated a program, building upon the BHGI experience to resource stratify cancer treatment guidelines across multiple cancer types and published NCCN Framework for resource stratification in breast cancer in 2016. Subsequently, the NCCN has published multiple additional resource stratification frameworks that use slightly different definitions of resource level than use by the BHGI. The American Society of Clinical Oncology (ASCO) has also assembled a Guidelines Advisory Group for Resource Stratification for different cancers, and published its first comprehensive resource-stratified guidelines for cancer of the cervix.

Summary

International efforts to improve management and reduce disparities in the outcome of breast cancer patients’ worldwide focus on recommendations for better allocation of available resources in different countries. The WHO, BHGI, NCCN, ASCO, and other international initiatives issued various resource-stratified guidelines (RSG) based on levels of resources in different countries. We shed the light on the development of these guidelines and discuss awareness, prevention of advanced disease at presentation, and management. Future research is needed to update and improve dissemination and implementation of RSG, as well as building infrastructure, reforming of health systems, and better allocating resources.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. International Agency for Research on Cancer. World Health Organization, gco.iarc.fr/today/home, Accessed March 29, 2018.

  2. Anderson BO, Ilbawi AM, El Saghir NS. Breast cancer in low and middle income countries (LMICs): a shifting tide in global health. Breast J. 2014;21:111–8. https://doi.org/10.1111/tbj.12357.

    Article  PubMed  Google Scholar 

  3. WHO. National cancer control programmes: policies and managerial guidelines. Geneva: WHO; 2002. Access at http://wwwwhoint/cancer/media/en/408pdf, April 17, 2018

    Google Scholar 

  4. Anderson BO, Braun S, Carlson RW, et al. Overview of breast health care guidelines for countries with limited resources. Breast J. 2003;2:S42–5035.

    Article  Google Scholar 

  5. Anderson BO, Yip C, Ramsey SD, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006;12(s1):S54–69.

    Article  PubMed  Google Scholar 

  6. Anderson BO, Cazap E, El Saghir NS, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol. 2011;12:387–98.

    Article  PubMed  Google Scholar 

  7. •• Distelhorst SR, Cleary JF, Ganz PA, et al. Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. Lancet Oncol. 2015;16(3):e137–47. https://doi.org/10.1016/S1470-2045(14)70457-7. ISSN 1470–2045, (http://www.sciencedirect.com/science/article/pii/S1470204514704577). This article combined the three successive BHGI panel recommendations into a comprehensive summary, including the importance of supportive and palliative care in breast cancer patients in LMICs as much as recommendations with curative intents.

    Article  PubMed  Google Scholar 

  8. Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH, Bese NS, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J. 2006 Jan-Feb;12 Suppl 1:S3–15. https://doi.org/10.1111/j.1075-122X.2006.00199.x.

  9. •• Carlson RW, Scavone JL, Koh WJ, et al. NCCN Framework for resource stratification: a framework for providing and improving global quality oncology care. J Natl Compr Cancer Netw. 2016;14:961–9. This study shows the need and necessity of having RSGs to treat better cancer patients in LMICs, and offers the most updated RSGs made in 2016 by the NCCN Framework.

    Article  Google Scholar 

  10. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, et al. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer. 2008 Oct 15;113(8 Suppl):2269–81. https://doi.org/10.1002/cncr.23843.

  11. National Comprehensive Cancer Network. NCCN Harmonized GuidelinesTM for Sub-Saharan Africa. Breast Cancer. (Version 2.2017 – November 3, 2017). https://www.nccn.org/professionals/physician_gls/pdf/breast_harmonized-africa.pdf. Accessed June 24 2018.

  12. Erickson Foster J, Velasco JM, Hieken TJ. Adverse outcomes associated with noncompliance with melanoma treatment guidelines. Ann Surg Oncol. 2008;15:2395–402. https://doi.org/10.1245/s10434-008-0021-0.

    Article  PubMed  Google Scholar 

  13. Neubauer MA, Hoverman JR, Kolodziej, et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non–small-cell lung cancer in the community setting. J Oncol Pract. 2010;6(1):12–8. https://doi.org/10.1200/JOP.091058.

    Article  PubMed  Google Scholar 

  14. Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF. Failure to comply with NCCN Guidelines for the management of pancreatic cancer compromises outcomes. HPB. 2012;14:539–47. https://doi.org/10.1111/j.1477-2574.2012.00496.x.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Molena D, Mungo B, Stem M, Poupore AK, Chen SY, Lidor AO. Does quality of care matter? A study of adherence to National Comprehensive Cancer Network Guidelines for patients with locally advanced esophageal cancer. J Gastrointest Surg. 2015;19:1739–47. https://doi.org/10.1007/s11605-015-2899-8.

    Article  PubMed  Google Scholar 

  16. Delhorme J, Antoni D, Mak KS, et al. Treatment that follows guidelines closely dramatically improves overall survival of patients with anal canal and margin cancers. Crit Rev Oncol Hematol. 2016;101:131–8. https://doi.org/10.1016/j.critrevonc.2016.03.001. ISSN 1040–8428. (http://www.sciencedirect.com/science/article/pii/S1040842816300427)

    Article  PubMed  Google Scholar 

  17. Schwam ZG, Sosa JA, Roman S, et al. Receipt of care discordant with practice guidelines is associated with compromised overall survival in nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2016;28:1–8.

    Article  Google Scholar 

  18. Yip CH, Smith RA, Anderson BO, et al. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008;113(8 Suppl):2244–56.

    Article  PubMed  Google Scholar 

  19. Dey S. Preventing breast cancer in LMICs via screening and/or early detection: the real and the surreal. World J Clin Oncol. 2014;5:509–19.

    Article  PubMed  PubMed Central  Google Scholar 

  20. El Saghir NS, Farhat RA, Charara RN, et al. Enhancing cancer care in areas of limited resources: our next steps. Future Oncol. 2014;10:1953–65.

    Article  PubMed  CAS  Google Scholar 

  21. Hayek F, Berro B, Fayad W. Awareness campaign for the early detection of growth disorders in public school children in North Lebanon. Ethn Dis. 2016;26(3):417–26. https://doi.org/10.18865/ed.26.3.417.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Shyyan R, Sener SF, Anderson BO, Fernández Garrote LM, Hortobágyi GN, Ibarra JA Jr, et al. Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation. Cancer. 2008;113(8 Suppl):2257–68.

    Article  PubMed  Google Scholar 

  23. Mayor S. Radiation in combination with immune-checkpoint inhibitors. Lancet Oncol. 2015;16:e162. https://doi.org/10.1016/S1470-2045(15)70118-X.

    Article  PubMed  Google Scholar 

  24. Rugo HS, Barve A, Waller CF, et al. Heritage: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. ASCO Annual Meeting; Chicago, IL; Jun 3–7, 2016. LBA503.

  25. Cardoso E, Senkus A, Costa E, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4). Ann Oncol. 2018. https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy192/5055519.

  26. Yip CH, Cazap E, Anderson BO, et al. Breast cancer management in middle-resource countries: consensus statement from the Breast Health Global Initiative. Breast, April 2011; 20 (TBD).

  27. Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015;16:1193–224.

    Article  PubMed  Google Scholar 

  28. Grover S, Xu MJ, Yeager A, et al. A systematic review of radiotherapy capacity in low- and middle-income countries. Front Oncol. 2015;4:380. https://doi.org/10.3389/fonc.2014.00380. eCollection 2014

    Article  PubMed  PubMed Central  Google Scholar 

  29. Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16:1153–86.

    Article  PubMed  Google Scholar 

  30. Robertson J, Barr R, Shulman LN, Forte GB, Magrini N. Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ. 2016;94:735–42. https://doi.org/10.2471/BLT.15.163998.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741–8.

    Article  PubMed  CAS  Google Scholar 

  32. Joensuu H, Fraser J, Wildiers H, et al. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer. The Synergism Or Long Duration (SOLD) trial. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5–9, 2017; San Antonio, TX. Abstract GS3–04.

  33. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685–92.

    Article  PubMed  CAS  Google Scholar 

  34. •• El Saghir NS, Kreidieh FY, El-Baba S, Anderson BO. Management of locally advanced and metastatic breast cancer: guidelines, infrastructures and low resource settings. Breast Cancer Manage. 2016;5(2):69–77. This article tackles a specific group of patients in LMICs, which is the locally advanced/metastatic breast cancer group. It is important to know that resources needed in the management of cancer at this advanced stage requires proper infrastructure that is not always present in low-resource countries. In this article, disparities in the breast cancer outcomes and requirements for optimal management are reviewed, including infrastructure needs for optimal surgery, radiation treatment, and systemic therapy. In addition, the article mentions controversies related to drug pricing and availability and process and delays in registration of new drugs as well as resource stratification.

    Article  CAS  Google Scholar 

  35. El Saghir NS, Adebamowo CA, Anderson BO, et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast. 2011;20:S3–S11.

    Article  PubMed  Google Scholar 

  36. Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, et al. Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast. 2013;22:606–15.

    Article  PubMed  Google Scholar 

  37. Lopes G, Eniu A, El Saghir N. Developing resource-stratified guidelines in oncology to improve cancer care worldwide. 2015. Asco Post, https://am.asco.org/developing-resource-stratified-guidelines-oncology-improve-cancer-care-worldwide.

  38. Cazap E, Distelhorst SR, Anderson BO. Implementation science and breast cancer control: a Breast Health Global Initiative (BHGI) perspective from the 2010 Global Summit. Breast. 2011;20(suppl 2):S1–2.

    Article  PubMed  Google Scholar 

  39. Charara RN, Kreidieh FY, Farhat RA, al-Feghali KA, Khoury KE, Haydar A, et al. Practice and impact of multidisciplinary tumor boards on patient management: a prospective study. J Glob Oncol. 2016;3:242–9. https://doi.org/10.1200/JGO.2016.004960.

    Article  PubMed  PubMed Central  Google Scholar 

  40. El Saghir NS, Carlson RW, Khoury KE, Fallowfield L. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of cancer patients worldwide. Am Soc Clin Oncol Educ Book. 2014;2014:e461–6.

    Article  Google Scholar 

  41. El Saghir N, El Asmar N, Hajj C, et al. Survey of utilization of multidisciplinary management tumor boards in Arab countries. Breast. 2011;20(Suppl 2):S70–4.

    Article  PubMed  Google Scholar 

  42. El Saghir NS, Charara RN, Kreidieh FY, et al. Global practice and efficiency of multidisciplinary tumor boards: results of an American Society of Clinical Oncology international survey. J Global Oncol. 2015;1:57–64.

    Article  Google Scholar 

  43. WHO. Health systems: equity; http://www.who.int/healthsystems/topics/equity/en/ Accessed March 30, 3018.

  44. Hortobagyi GN, El-Saghir NS, Cufer T, et al. The American Society of Clinical Oncology’s efforts to support global cancer medicine. J Clin Oncol. 2016;34(1):76–82. https://doi.org/10.1200/JCO.2015.61.7696.

    Article  PubMed  CAS  Google Scholar 

  45. B O. Anderson, A Dvaladze, A Ilbawi, et al. Prevention: breast cancer risk factors and risk reduction https://www.fredhutch.org/en/labs/phs/projects/breast-cancer-initiative_2-5/knowledge-summaries.html. Accessed on June 26, 2018.

  46. B O. Anderson, A Dvaladze, A Ilbawi, et al. Early detection: screening mammography programs. https://www.fredhutch.org/en/labs/phs/projects/breast-cancer-initiative_2-5/knowledge-summaries.html. Accessed on June 26, 2018.

  47. B. O. Anderson, A Dvaladze, A Ilbawi, et al. Treatment: systemic therapy: chemotherapy for breast cancer. https://www.fredhutch.org/en/labs/phs/projects/breast-cancer-initiative_2-5/knowledge-summaries.html. Accessed on June 26, 2018.

  48. B O. Anderson, A Dvaladze, A Ilbawi et al. Palliative care during treatment for breast cancer. https://www.fredhutch.org/en/labs/phs/projects/breast-cancer-initiative_2-5/knowledge-summaries.html. Accessed on June 26, 2018.

  49. El Saghir NS. Conflict medicine and cancer care in refugees and displaced people. Asco Connection 2017, https://connection.asco.org/blogs/conflict-medicine-and-cancer-care-refugees-and-displaced-people.

  50. •• El Saghir NS, Perez de Celis ES, Fares JE, Sullivan R. Cancer care for refugees and displaced populations: Middle East conflicts and global natural disasters. 2018 American Society of Clinical Oncology ASCO Educational Book: http://ascopubs.org/doi/abs/10.1200/EDBK_201365. This article brings a new dimension to the subject of underprivileged cancer patients, which are refugees and displaced populations. It incites the WHO, UN, BHGI, ASCO, NCCN, and others to think about solutions for cancer patients in these communities.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box: 11-0236, Riad El Solh, Beirut, 1107 2020, Lebanon

    Nagi S. El Saghir & Paul A. El Tomb

  2. National Comprehensive Cancer Network, Fort Washington, PA, USA

    Robert W. Carlson

  3. Stanford University Medical Center, Palo Alto, CA, USA

    Robert W. Carlson

  4. Fox Chase Cancer Center, Philadelphia, PA, USA

    Robert W. Carlson

Authors
  1. Nagi S. El Saghir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul A. El Tomb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert W. Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nagi S. El Saghir.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Global Breast Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Saghir, N.S., El Tomb, P.A. & Carlson, R.W. Breast Cancer Diagnosis and Treatment in Low- and Mid-Resource Settings: the Role of Resource-Stratified Clinical Practice Guidelines. Curr Breast Cancer Rep 10, 187–195 (2018). https://doi.org/10.1007/s12609-018-0287-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-018-0287-6

Keywords

Search

Navigation